Exploring neuroendocrine carcinoma of the cervix: a case report and literature review

Sumedha Gupta; Dheer Singh Kalwaniya; Varsha Motwani

doi:10.18203/2320-1770.ijrcog20241093

Authors

Sumedha Gupta Department of Obstetrics and Gynaecology, VMMC and SJH, New Delhi, India
Dheer Singh Kalwaniya Department of General Surgery, VMMC and SJH, New Delhi, India
Varsha Motwani Department of Obstetrics and Gynaecology, VMMC and SJH, New Delhi, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20241093

Keywords:

Carcinoma cervix, Immunohistochemistry, Neuroendocrine neoplasia, Cervix

Abstract

Neuroendocrine neoplasms (NENs) are rare, comprising less than 1% of cervical malignancies. Diagnosis and management of cervical neuroendocrine carcinoma (NEC) pose challenges due to its rarity and aggressive nature. Aim of the study was to highlight the importance of considering NEC in the differential diagnosis of cervical malignancies and underscore the potential benefits of comprehensive treatment approaches. We report a case of a 35-year-old woman presenting with post-coital bleeding, subsequently evaluated and diagnosed with NEC T1b1N0Mx following radical hysterectomy. Adjuvant chemoradiotherapy and chemotherapy led to one year of remission. Cervical NEC poses diagnostic and therapeutic challenges due to its rarity and aggressive nature. Despite multimodal treatment, prognosis remains poor, warranting further research and targeted therapies. The rarity of cervical NEC emphasizes the need for increased awareness among clinicians to facilitate early detection and appropriate management. Further studies are warranted to explore novel treatment modalities and improve outcomes for patients with this challenging malignancy.

Metrics

Metrics Loading ...

References

Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589-97.

Pape UF, Berndt U, Müller-Nordhorn J, Bo ̈hmig M, Roll S, Koch M, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008;15(4):1083-97.

Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ. 2007;189(10):E398-404.

Gadducci A, Carinelli S, Aletti G. Neuroendocrine tumors of the uterine cervix: a therapeutic challenge for gynecologic oncologists. Gynecol Oncol. 2017;144(3):637-46.

Alejo M, Alemany L, Clavero O, Quiros B, Vighi S, Seoud M, et al. Contribution of human papillomavirus in neuroendocrine tumors from a series of 10,575 invasive cervical cancer cases. Papillomavirus Res. 2018;1(5):134-42.

Tempfer CB, Tischoff I, Dogan A, Hilal Z, Schultheis B, Kern P, et al. Neuroendocrine carcinoma of the cervix: a systematic review of the literature. BMC Cancer. 2018;4(18):530.

Salvo G, Gonzalez Martin A, Gonzales NR, Frumovitz M. Updates and management algorithm for neuroendocrine tumors of the uterine cervix. Int J Gynecol Cancer. 2019;29:986-95.

Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R: Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143(2):22-36.

Tabbara SO, Khalbuss WE. Other malignant neoplasms. The Bethesda System for Reporting Cervical Cytology. Nayar R, Wilbur DC (ed): Springer, Switzerland; 3rd edition 2015;244-6.

McCluggage WG, Kennedy K, Busam KJ. An immunohistochemical study of cervical neuroendocrine carcinomas: neoplasms that are commonly TTF1 positive and which may express CK20 and P63. Am J Surg Pathol. 2010;34(4):525-32.

Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, et al. Exceptional response to nivolumab and stereotactic body Radiation therapy (SBRT) in neuroendocrine cervical carcinoma with high tumor mutational burden: management considerations from the Center for Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017;22(6):631-7.